Pfizer's RSV vaccine sales decline but market share shows promising growth

Pfizer's sales of its RSV vaccine, Abrysvo, declined in the third quarter compared to the same period last year. However, the company remains optimistic about its market potential and has seen an increase in market share.

Pfizer's Market Share and Revenue

The total revenue from Abrysvo for the first nine months of the year has significantly risen due to the timing of the vaccine's approval for older adults in the U.S. Pfizer's market share has surpassed 50% of the shipped volume for the third quarter, despite competition from GSK.

Changes in RSV Vaccination Volumes

The Centers for Disease Control and Prevention (CDC) has updated its guidance on RSV vaccinations, leading to a decrease in vaccination volumes among older adults. However, there has been a surge in maternal vaccinations, which is seen as a promising avenue for growth.

Pfizer's Next-Generation Vaccines

Pfizer is also developing next-generation pneumococcal vaccines to replace its top-selling Prevnar 20, but faces competition in this market. Analysts have expressed concerns about Pfizer's ability to compete effectively.

Conclusion

In summary, Pfizer is strategically positioning itself to capture a larger market share and expand its product offerings, but faces challenges in the evolving regulatory landscape and competitive pressures.

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings